210 results on '"Scott, Jeanette"'
Search Results
2. Oral corticosteroid dosage and tapeduration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse
3. Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study
4. Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60.
5. Is multiple sclerosis a glymphaticopathy?
6. The MacGyver bias and attraction of homemade devices in healthcare
7. 8 Dosing of oral corticosteroid therapy and the risk of relapse at the onset of MOGAD
8. 2675 Longitudinal epidemiology of multiple sclerosis in Townsville, Queensland, Australia 2012–2022
9. 6 Spike antibody seroconversion and emerging variant cross-reactivity following COVID-19 third vaccination dose in Australian people with multiple Sclerosis
10. Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies.
11. A pro-inflammatory diet in people with multiple sclerosis is associated with an increased rate of relapse and increased FLAIR lesion volume on MRI in early multiple sclerosis: A prospective cohort study
12. MIGRAINE AND MULTIPLE SCLEROSIS: THE FINAL ANSWER?
13. Combination of transnasal humidified rapid-insufflation ventilatory exchange with high frequency jet ventilation for shared airway surgery
14. Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse
15. Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60
16. Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination
17. Cancer risk and mortality in multiple sclerosis: The need for vigilance
18. sj-docx-1-msj-10.1177_13524585231167739 – Supplemental material for A pro-inflammatory diet in people with multiple sclerosis is associated with an increased rate of relapse and increased FLAIR lesion volume on MRI in early multiple sclerosis: A prospective cohort study
19. The biological rabbit hole: Only for the blind
20. FROM BENCH TO BEDSIDE: A SNAIL IN TREACLE?
21. Mr. Machiavelli's Choice for Treatment of MOG Antibody Disease: Do the benefits of long-term corticosteroids justify the means?
22. Training Parents and Teachers in Remedial Reading Procedures for Children with Learning Difficulties
23. 2263 Long-term safety of ofatumumab in patients with relapsing multiple sclerosis
24. 2326 Differential methylation mediates significant proportions of environmental and lifestyle factors’ associations with MS risk: results from the Ausimmune case-control study
25. 2258 Novel generation of real-world evidence through MSGo, a digital support program supporting the use of siponimod in secondary progressive multiple sclerosis patients in Australia
26. 2327 Latitude, UVR and multiple sclerosis severity
27. 2432 Spike antibody seroconversion and breadth following SARS-CoV-2 vaccination in Australian people with Multiple Sclerosis
28. EBV as the “gluten of MS” hypothesis provides a rationale for trialing antiviral therapies
29. Onset of multiple sclerosis is preventable – time to act now!
30. Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS
31. Long-term trajectories of employment status, workhours and disability support pension status, after a first episode of CNS demyelination
32. sj-docx-1-msj-10.1177_13524585221089900 – Supplemental material for Long-term trajectories of employment status, workhours and disability support pension status, after a first episode of CNS demyelination
33. Diagnosis of multiple sclerosis: Progress or confusion?
34. The difficult airway with recommendations for management – Part 1 – Difficult tracheal intubation encountered in an unconscious/induced patient
35. The difficult airway with recommendations for management – Part 2 – The anticipated difficult airway
36. 010 Real-world experience with ocrelizumab in the MSBase registry – Australian RRMS cohort
37. Melatonin and multiple sclerosis
38. Comment on Varghese and Kundu, does the Miller blade truly provide a better laryngoscopic view and intubating conditions than the Macintosh blade in small children?
39. Treatment Satisfaction in Patients with Highly-active Relapsing Multiple Sclerosis Treated with Cladribine Tablets: CLARIFY-MS Study Interim Analysis (1925)
40. How a pandemic affects the mental\ud health of the nursing workforce
41. Contributors
42. Intubating Introducers, Stylets, and Lighted Stylets (Lightwands)
43. Is multiple sclerosis overdiagnosed?
44. Is the incidence of multiple sclerosis really increasing?
45. The MSReactor computerized cognitive battery correlates with the processing speed test in relapsing-remitting multiple sclerosis
46. High Prudent diet factor score predicts lower relapse hazard in early multiple sclerosis
47. The future of microbiome research in neuroinflammatory disorders
48. Big pharma and social responsibility
49. “Is this new medicine going to help me walk again?”
50. How did the Macintosh laryngoscope become so popular?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.